Tazemetostat Hydrobromide
Phase 1Small molecule
Tazemetostat Hydrobromide is one of 58 small molecule programs targeting Clinical Stage IV Cutaneous Melanoma AJCC v8. It is currently in Phase 1.
2
Indications
2
Total Trials
2
Active Trials
57
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
154 competitors in Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1Taxol
TevaPhase 3
Imfinzi
AstraZenecaPhase 3
Tecentriq
RochePhase 3
Camptosar
PfizerPhase 3
Keytruda
Merck & Co.Phase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Avastin
RochePhase 3
Vepesid
AAvyxa
Phase 3
Opdivo
Bristol-Myers SquibbPhase 3
Tarlatamab-Dznl
AmgenPhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Small Cell Lung Cancer1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Tazemetostat Hydrobromide. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- NNational Cancer Institute (NCI)